Results from a phase I clinical trial of HBED.
Results from a phase I clinical trial of HBED.
复制标题
HBED I 期临床试验的结果。
DOI：
10.1007/978-1-4615-2554-7_37
复制
发表时间：
1994
影响因子：
--
通讯作者：
Giardina,PJ
中科院分区：
文献类型：
--
作者：
Grady,RW;Salbe,AD;Hilgartner,MW;Giardina,PJ
过去十几年的经验清楚地表明，除血色素沉着症外，铁在多种疾病的发病机制中起着重要作用。在类风湿性关节炎和再灌注损伤的病例中，铁催化自由基的形成，自由基破坏细胞膜，从而导致组织损伤。封存这些铁元素将在很大程度上避免这种损害。在淋巴促生长疾病和疟疾等寄生虫病中，铁是细胞分裂的必需营养素。不含铁会抑制细胞分裂，从而减缓这类疾病的发展。虽然不太可能影响治疗，铁螯合无疑是有益的辅助治疗这些和相关疾病。
The experience of the past dozen years clearly indicates that iron plays a significant role in the pathogenesis of a wide variety of disease states apart from hemochromatosis.1In cases of rheumatoid arthritis and reperfusion injury, iron catalyzes the formation of free radicals which destroy membranes and thereby lead to tissue damage. Sequestration of this iron would obviate much of this damage. In lymphopro-liferative disorders and parasitic diseases such as malaria, iron serves as an essential nutrient for dividing cells. Withholding iron would inhibit cell division and hence slow the progression of such diseases. While unlikely to affect cures, chelation of iron would undoubtedly be of benefit as adjunctive therapy in these and related disorders.